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Several factors, including changed dynamics of erythrocyte formation and degradation, can
influence the degree of hemoglobin A1c (HbA1c) formation thereby affecting its use in moni-
toring diabetes. This study determines the influence of whole blood donation on HbA1c in
both non-diabetic blood donors and blood donors with type 2 diabetes.
Methods
In this observational study, 23 non-diabetic blood donors and 21 blood donors with type 2
diabetes donated 475 mL whole blood and were followed prospectively for nine weeks.
Each week blood samples were collected and analyzed for changes in HbA1c using three
secondary reference measurement procedures.
Results
Twelve non-diabetic blood donors (52.2%) and 10 (58.8%) blood donors with type 2 diabe-
tes had a significant reduction in HbA1c following blood donation (reduction >-4.28%, P <
0.05). All non-diabetic blood donors with a normal ferritin concentration predonation had a
significant reduction in HbA1c. In the non-diabetic group the maximum reduction was
-11.9%, in the type 2 diabetes group -12.0%. When eligible to donate again, 52.2% of the
non-diabetic blood donors and 41.2% of the blood donors with type 2 diabetes had HbA1c
concentrations significantly lower compared to their predonation concentration (reduction
>-4.28%, P < 0.05).
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Conclusion
Patients with type 2 diabetes contributing to whole blood donation programs can be at risk of
falsely lowered HbA1c. This could lead to a wrong interpretation of their glycemic control by
their general practitioner or internist.
Introduction
Hemoglobin A1c (HbA1c) is used worldwide in the diagnosis and monitoring of type 2 diabe-
tes. However, HbA1c can only be interpreted correctly when erythropoiesis and erythrocyte
survival are uncompromised. Several conditions such as iron deficiency, (severe) kidney insuf-
ficiency and the presence of a hemoglobin variant can lead to an under- or overestimation of
HbA1c, affecting correct interpretation of glycemic control [1].
When blood donors donate blood they lose approximately one tenth of their blood volume.
Consequently they lose one tenth of preformed HbA1c. The bone marrow will compensate the
blood loss by an increase in erythropoiesis, resulting in an increased flow of newly formed
erythrocytes devoid of HbA1c. As glycation of hemoglobin is a relatively slow chemical process
[2], the increased synthesis of erythrocytes will therefore, theoretically, result in a drop in
HbA1c for a number of weeks. Previous research has indeed suggested that blood loss and/or
whole blood donation can affect HbA1c formation [3,4]. However, the precise effect of whole
blood donation on HbA1c dynamics has not been thoroughly studied and blood donors diag-
nosed with type 2 diabetes haven’t been included in previous research. In addition, the inter-
play between iron availability, erythropoiesis and HbA1c following whole blood donation is
unknown. Within the Dutch donor population the self-reported incidence of type 2 diabetes is
0.9% [5]. As in most countries volunteers with type 2 diabetes are eligible to donate blood, this




Two groups of volunteers at Sanquin, the Dutch national blood service collection center
(Zwolle, the Netherlands), were followed prospectively after whole blood donation. For this
observational study, one group consisted of 23 non-diabetic blood donating volunteers, the
other group consisted of 21 blood donating volunteers with type 2 diabetes. Both groups were
matched in age and gender and fulfilled the eligibility criteria for donating whole blood in the
Netherlands (Sanquin, Amsterdam, the Netherlands). The volunteers with type 2 diabetes
were selected from the Sanquin blood donor database on the basis of their use of diabetes med-
ication. Subsequently, age and gender matched non-diabetic volunteers were selected to
reduce bias. The study (NL47160.075.13) was approved by Sanquin’s institutional review
board and the Medical Ethics Review Committee (Isala Hospital, Zwolle, the Netherlands).
Written informed consent was obtained from all volunteers.
Procedure
Blood donors were followed prospectively for nine weeks. In the first week they voluntarily
donated 475 mL of whole blood and two extra test tubes were collected for determining HbA1c
and confounding factors: urea, creatinine, gamma-glutamyl transpeptidase, aspartate
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transaminase, alanine transaminase, C-reactive protein (CRP) and ferritin. In addition, hema-
tological parameters were determined (hemoglobin, hematocrit, mean corpuscular volume,
reticulocytes and reticulocyte hemoglobin content). In the subsequent weeks each blood
donor visited the center on the same weekday as the weekday of whole blood donation for col-
lecting two test tubes for determining HbA1c, CRP, ferritin and hematological parameters.
Vitamin B12 and folic acid were determined predonation and 4 weeks post donation to moni-
tor vitamin status which could affect erythropoiesis. Predonation (baseline) characteristics of
HbA1c, ferritin, hemoglobin, vitamin B12 and folic acid are listed in Table 1.
Test tubes were labeled anonymously before being sent to the laboratory and were analyzed
within three hours at the clinical chemical laboratory of the Isala hospital (Zwolle, the Nether-
lands). Samples for HbA1c were stored at -80˚C and analyzed at the end of the study in one
run for each donor to prevent bias. All volunteers had donated previously without any prob-
lems. Each week volunteers were asked whether there was any change in diet, medication,
health status, infection or other particulars. The study was performed from January until
March 2015.
Laboratory measurements
HbA1c analysis was performed at the European Reference Laboratory for Glycohemoglobin
(Zwolle, the Netherlands). HbA1c measurements were performed in duplicate at the end of the
study in a single run for each blood donor. HbA1c was measured using 3 different secondary
reference measurement procedures (SRMP) certified by the International Federation of Clini-
cal Chemistry and Laboratory Medicine and the National Glycohemoglobin Standardization
Program (IFCC and NGSP): Roche Tina-quant HbA1c Gen.2 on Integra 800, immunoassay,
Table 1. Subject demographics and baseline characteristics.
Healthy group mean (sd) Diabetes group mean (sd) Reference interval
Total number of participants 23 21
Age (years) 60.8 (6.3) 61.7 (6.9)
Female (n) / male (n) 2 / 21 2 / 19
BMI (kg/m2) 27.0 (3.1) 28.6 (3.5)
Ethnicity 100% white 100% white
Number of blood donations per donor in 2014 3.6 (0.79) 2.1 (1.67)
Diabetes medication:
metformin (n) 0 10
metformin & sulfonylurea (n) 0 7
metformin & DPP-4 inhibitor (n) 0 1
metformin & DPP-4 inhibitor & sulfonylurea (n) 0 2
metformin & GLP-1 mimetic & sulfonylurea (n) 0 1
Baseline hemoglobin (g/dL) female 12.9 (0.33) 14.0 (1.37) 12.1–16.1
Baseline hemoglobin (g/dL) male 14.5 (0.92) 14.0 (0.80) 13.7–17.7
Baseline HbA1c (%) 5.6 (0.38) 6.8 (0.74) 4.0–6.0
Baseline HbA1c (mmol/mol) 37.9 (4.2) 51.5 (8.0) 20–42
Baseline ferritin (μg/L) female 32.5 (16.3) 34 (8.5) 20–150
Baseline ferritin (μg/L) male 37.1 (24.3) 58.4 (35.6) 30–350
Baseline vitamin B12 (pmol/L) 300 (84.7) 348 (192.7) 150–700
Baseline folic acid (nmol/L) 21.5 (7.2) 20.6 (6.4) 5–40
DDP-4: dipeptidyl peptidase-4, GLP-1: glucagon-like peptide-1
doi:10.1371/journal.pone.0170802.t001
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IFCC and NGSP certified (Roche Diagnostics, Almere, the Netherlands); Premier Hb9210,
affinity chromatography HPLC, IFCC and NGSP certified (Trinity Biotech, Bray, Ireland);
Tosoh G8, cation-exchange HPLC, IFCC certified (Tosoh Bioscience, Griesheim, Germany).
The SRMP’s have documented good results in the IFCC and NGSP monitoring programs and
were calibrated using the IFCC secondary reference material with assigned IFCC and derived
NGSP values [6–8].
The analytical coefficients of variation (CVa) for the individual analyzers used in this study
were determined: Tosoh G8 CVa 0.69% (IFCC) and CVa 0.41% (DCCT); Premier Hb9210 CVa
0.73% (IFCC) and CVa 0.43% (DCCT); Tina-quant CVa 1.91% (IFCC) and CVa 1.11%
(DCCT).9 Three different SRMP’s were used to show the possible variations between the dif-
ferent analyzers. Hematological parameters were measured using a XN-9000 hematology ana-
lyzer (Sysmex, Etten-Leur, the Netherlands). All other parameters were measured using a
Cobas 8000 analyzer (Roche Diagnostics, Almere, the Netherlands).
Data analysis and statistics
Data analysis was performed using Graphpad Prism 6 (GraphPad Software, California,
USA). Comparisons between different groups were performed using the two-tailed
Mann-Whitney test. P values <0.05 were considered significant. Statistical dependence
between two variables was assessed using Spearman’s rho. The reference change value




), used for the assessment of the significance of differ-
ences in serial HbA1c results from individual subjects, was calculated using the analytical
coefficient of variation and the within-subject biological variation (CVw) of each HbA1c
assay method mentioned above [9]. The RCV and % HbA1c change or reduction from base-
line used throughout the article are based on SI units (mmol/mol) unless stated otherwise.
For the non-blood donating group [9] a two-tailed RCV was calculated using a Z value of
1.96 (P< 0.05) for interpretation of the change in HbA1c. For the non-diabetic group and
the group with type 2 diabetes donating whole blood, an one-tailed RCV was calculated
using a Z value of 1.65 (P < 0.05) for interpretation of the expected reduction in HbA1c
[10]. Two volunteers missed one out of 8 follow-up appointments, both appeared on the
appointment on the last scheduled visit. Percentage HbA1c decrease was calculated omit-
ting these missing data points, possibly resulting in an underestimation of the maximum
HbA1c reduction in two volunteers.
Results
A total of 44 blood donors (40 male/4 female) participated (Table 1). All blood donors with
type 2 diabetes were on metformin medication, 11 blood donors with type 2 diabetes received
additional glucose lowering medication (Table 1). Each blood donor with type 2 diabetes
reported having a good glycemic control and was not on insulin treatment in accordance with
the directive for donating blood in the Netherlands. The presence of comorbidities (e.g. high
blood pressure, benign prostatic hypertrophy and others) and additional medicine use (e.g.
lisinopril, tamsulosin and others) did meet Sanquin’s eligibility criteria for whole blood
donation.
In the course of the study, 16 blood donors reported having symptoms consistent with a
common cold, 3 blood donors had symptoms consistent with gastroenteritis and one blood
donor suffered from a bronchitis and was the only one receiving antibiotics. Of these in total
20 blood donors, 9 had an elevated CRP (5 mg/L). In addition, 2 blood donors had an ele-
vated CRP without medical complaints. During the whole study the maximum CRP found was
35 mg/L. Urea was slightly elevated in 16 blood donors, with a maximum of 10.1 mmol/L
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(reference range 2.9–7.5 mmol/L). Gamma-glutamyl transpeptidase was elevated in 6 blood
donors with a maximum of 97 U/L (reference range<55 U/L). Creatinine, folic acid and
aspartate transaminase were normal. One blood donor had an elevated vitamin B12 due to
monthly injections (847 pmol/L) and 4 blood donors had a suboptimal vitamin B12 concentra-
tion with a minimum of 99 pmol/L (reference range 150–700 pmol/L). Four weeks post dona-
tion 3 of these 4 blood donors showed an increase in vitamin B12 concentration within the
reference range. Six blood donors had mildly elevated alanine transaminase levels (reference
range<45 U/L). Considering the predonation hematological parameters, hemoglobin was
slightly below the reference range in 7 blood donors. The lowest hemoglobin measured was
12.3 g/dL in 2 male blood donors (reference range 13.7–17.7 g/dL).
Effect of whole blood donation on HbA1c
Previously, the biological variation of HbA1c in 20 non-blood donating volunteers during a 2
month period was determined [9]. Calculations using data in SI units (mmol/mol) from that
study showed that the biological variation in HbA1c varied in both positive and negative direc-
tion from baseline with three volunteers exceeding the RCV (Tosoh G8: mean change -0.57%
(95% CI -2.71%, 1.57%)) (Fig 1A).
Fig 1. Percentage HbA1c reduction from baseline during 8 weeks post whole blood donation. Data (Tosoh G8) is shown as box plots
each representing one individual. Horizontal dotted lines represent the RCV calculated for SI units. Box plots exceeding the RCV represent a
significant change or reduction in HbA1c concentration. A: Control group of 20 non-diabetic volunteers not donating whole blood.9 (Tosoh G8
two-tailed RCV ±5.1%) B: 23 non-diabetic blood donors after 475 mL whole blood donation. (Tosoh G8 one-tailed RCV -4.28%) C: 17 blood
donors with type 2 diabetes after 475 mL whole blood donation. (Tosoh G8 one-tailed RCV -4.28%) D: 17 blood donors with type 2 diabetes
after 475 mL whole blood donation represented in DCCT units. (Tosoh G8 one-tailed RCV -2.52%) E: 4 blood donors with type 2 diabetes
with an increase in HbA1c after 475 mL whole blood donation which were excluded from further analysis. (Tosoh G8 one-tailed RCV -4.28%)
doi:10.1371/journal.pone.0170802.g001
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Following whole blood donation, both non-diabetic blood donors (Fig 1B) and blood
donors with type 2 diabetes (Fig 1C) showed a reduction in HbA1c. Twelve non-diabetic blood
donors (52.2%) and 10 blood donors with type 2 diabetes (58.8%) showed a significant reduc-
tion exceeding the RCV (Tosoh G8). The other two HbA1c SRMP’s also showed a significant
HbA1c reduction in both groups (Premier Hb9210: 13 non-diabetic blood donors (56.5%), 14
blood donors with type 2 diabetes (82.4%); Tina-quant: 8 non-diabetic blood donors (34.8%),
7 blood donors with type 2 diabetes (41,2%) (data not shown)). The mean reduction for the
non-diabetic group was -5.45% (95% CI -4.1%, -6.79%) with a maximum of -11.9% for Tosoh
G8 (Premier Hb9210: mean reduction -4.73% (95% CI -3.58%, -5.88%), maximum -11.0%;
Tina-quant: mean reduction -4.29% (95% CI -2.87%, -5.71%), maximum -9.6%). The mean
reduction for the group with type 2 diabetes was -6.0% (95% CI -4.54%, -7.51%) with a maxi-
mum of -12.0% for Tosoh G8 (Premier Hb9210: mean reduction -6.23% (95% CI -4.83%,
-7.67%), maximum -11.6%; Tina-quant: mean reduction -5.15% (95% CI -3.3%, -6.99%), max-
imum -16.3%). There was no significant difference in the maximum reduction of HbA1c
between non-diabetic blood donors and blood donors with type 2 diabetes. When analyzing
the data in DCCT units (%) for blood donors with type 2 diabetes, the reduction in HbA1c was
smaller (Tosoh G8: mean reduction -4.08% (95% CI -3.07%, -5.1%), maximum -8.7%) due to
the difference between DCCT and IFCC units [11]. More blood donors (13; 76.5%) exceeded
the RCV in DCCT units compared to IFCC units (10; 58.8%) (Tosoh G8) (Fig 1D). Four blood
donors with type 2 diabetes showed a sharp increase in HbA1c during follow up, probably due
to poor glycemic control and where excluded from further analysis (Fig 1E).
Ferritin status and HbA1c
A total of 17 blood donors didn’t show a significant reduction in HbA1c (Tosoh G8) after
whole blood donation (10 non-diabetic blood donors and 7 blood donors with type 2 diabe-
tes). A possible explanation could be a low ferritin concentration due to the frequency of dona-
tion, resulting in a less effective erythropoiesis and as a consequence a reduced effect on
HbA1c. In the Netherlands, male blood donors are allowed to donate whole blood up to 5
times a year, female blood donors up to 3 times a year. Some of these blood donors develop in
time a low ferritin concentration, because of the frequency of donation, and subsequently a
low hemoglobin concentration (minimum Hb for whole blood donation: male 13.5 g/dL,
female 12.6 g/dL) and aren’t allowed to donate blood for at least 3 months. When analyzing
ferritin concentrations predonation versus the maximum reduction in HbA1c in non-diabetic
blood donors a correlation between both parameters was observed (Pearson’s r = -0.65)
(Fig 2A).
Based on this we defined a ferritin concentration <30 μg/L as too low to have a significant
lowering effect on HbA1c after whole blood donation. A ferritin concentration <30 μg/L has
previously been suggested as a sensitive diagnostic cutoff value for iron deficiency [12]. To fur-
ther support this cutoff value, the predonation hemoglobin content of reticulocytes (immature
erythrocytes) in non-diabetic blood donors was analyzed. Reticulocyte hemoglobin content is
a parameter that can be used as an early indicator of functional iron deficiency as it reflects
bone marrow iron availability [13]. A significant difference in reticulocyte hemoglobin content
was found (P = 0.0004) when comparing the low (<30 μg/L) and the normal ferritin (>30 μg/
L) group: low ferritin concentration correlated with low reticulocyte hemoglobin content (Fig
2B). The mean reduction in HbA1c of the low and the normal ferritin groups was significantly
different for the non-diabetic blood donors (P< 0.0001). However, no significant difference
in the mean reduction in HbA1c was found between the low and normal ferritin blood donors
with type 2 diabetes (P = 0.69) (Fig 2C).
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Fig 2. Effect of ferritin concentration on maximum HbA1c reduction (Tosoh G8). Horizontal dotted lines
represent the Tosoh G8 one-tailed RCV (-4.28%) calculated for SI units. A: 23 non-diabetic blood donors
after 475 mL whole blood donation. The predonation ferritin concentration correlated significantly with the
Whole Blood Donation and HbA1c
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HbA1c dynamics after whole blood donation
The above presented data showed that whole blood donation resulted in a significant reduc-
tion in HbA1c concentration in more than 50% of the blood donors with a maximum between
-9.6% and -16.3% depending on the method used. Knowledge of the time points of maximum
HbA1c reduction and normalization are essential for diabetes care. In general, a larger maxi-
mum reduction in HbA1c was seen in the last weeks of the study, while a smaller maximum
reduction in HbA1c was seen in the first weeks post donation (non-diabetic Spearman’s r =
-0.668; type 2 diabetes Spearman’s r = -0.547) (Fig 3A and 3B).
Interestingly, almost none of the blood donors returned to their predonation HbA1c con-
centration at the end of the study, 8 weeks post donation. Taking the RCV into account, 52.2%
of the non-diabetic blood donors and 41.2% of the blood donors with type 2 diabetes didn’t
reach their predonation HbA1c concentration (Tosoh G8; Premier Hb9210: non-diabetic
43.5%, type 2 diabetes 52.9%; Tina-quant: non-diabetic 21.7%, type 2 diabetes 11.8%.) (Fig 3C
and 3D and data not shown). Almost all blood donors with a low predonation ferritin concen-
tration (Fig 3C and 3D orange lines) did not exceed the HbA1c RCV and as such did not devi-
ate significantly from their predonation HbA1c during the study.
Discussion
Statement of principal findings
Patients with type 2 diabetes contributing to whole blood donation programs can be at risk of
falsely lowered HbA1c concentrations which could lead to wrong interpretation and therapeu-
tic decision making by their general practitioner or internist. Our study showed that HbA1c
dropped significantly after whole blood donation in more than half of the blood donors
(Tosoh G8, Premier Hb9210). When correcting for normal ferritin concentrations, all healthy
blood donors showed a significant drop in HbA1c. The maximum reductions were dependent
on the HbA1c analyzer and assay method used (Tosoh G8 -12%, Premier Hb9210 -11.6%,
Tina-quant -16.3%). The differences in observed HbA1c reduction, especially for the Tina-
quant, are most likely related to differences in analytical coefficients of variation of the differ-
ent SRMP’s. There was no difference in relative maximum reduction in HbA1c between non-
diabetic blood donors and blood donors with type 2 diabetes. The significant HbA1c reduction
observed in our study in all blood donors with a normal ferritin concentration is likely to
reflect a general physiological phenomenon and as such would be expected to occur in all
whole blood donors.
Strengths and weaknesses in relation to other studies
Changes in HbA1c after whole blood donation have been studied previously. In 1985 Starkman
et al. showed a decrease in HbA1c with a maximal reduction after 4 weeks following blood loss
(450 mL) in a small group (n = 12) of non-diabetic volunteers [3]. More recently, a large group
maximum % decrease in HbA1c (Pearson’s r = -0.65, P = 0.0009). Volunteers without a significant decrease in
HbA1c had predonation ferritin concentrations <30 μg/L. B: Volunteers with ferritin concentrations <30 μg/L
had a significantly lower reticulocyte hemoglobin concentration compared to blood donors with ferritin
concentrations >30 μg/L (two-tailed Mann Whitney P = 0.0004). Data is presented as box plots. C: non-
diabetic blood donors and blood donors with type 2 diabetes divided into groups with low and normal
predonation ferritin concentration in relation to maximum % decrease HbA1c is plotted. A significant difference
in mean maximum % decrease HbA1c between low and normal ferritin concentration was observed for the
non-diabetic blood donors (two-tailed Mann Whitney P < 0.0001) but not for the blood donors with type 2
diabetes (two-tailed Mann Whitney P = 0.69).
doi:10.1371/journal.pone.0170802.g002
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(n = 42) of non-diabetic blood donors, who didn’t donate blood for at least 6 months, showed
no significant reduction in HbA1c after whole blood donation. However, the time points used
for HbA1c measurement were few and mostly short after whole blood donation (500 mL; 24
hours, 1 week, 2 weeks, 3 months) [4]. One study assessed the effect of blood-letting on HbA1c
in patients with type 2 diabetes. Blood-letting consisted of three phlebotomies (500 mL each)
at a 2-week interval with measurement of HbA1c at 4 and 12 months after the blood-letting
sequence. After 4 months a mean decrease of HbA1c of approximately 10% (based on DCCT
units) or 15% (based on SI units) was observed [14]. The strength of our study compared to
Fig 3. Dynamics of HbA1c during 8 weeks post whole blood donation (Tosoh G8). Horizontal dotted lines represent the Tosoh G8 one-
tailed RCV (-4.28%) calculated for SI units. A: 23 non-diabetic blood donors after 475 mL whole blood donation. A low maximum % reduction
in HbA1c correlated with an early time point in the study, a high maximum % reduction in HbA1c correlated with a late time point (Spearman
r = -0.668; P = 0.0005). B: Individual changes of HbA1c in 23 non-diabetic blood donors. The orange lines represent non-diabetic blood
donors with low ferritin (<30 μg/L). C: 17 blood donors with type 2 diabetes after 475 mL whole blood donation. A low maximum % reduction
in HbA1c correlated with an early time point in the study, a high maximum % reduction in HbA1c correlated with a late time point (Spearman
r = -0.547; P = 0.015). D: Individual changes of HbA1c in 17 blood donors with type 2 diabetes. The orange lines represent blood donors with
type 2 diabetes with low ferritin (<30 μg/L).
doi:10.1371/journal.pone.0170802.g003
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the ones mentioned above is the inclusion of both non-diabetic blood donors and blood
donors with type 2 diabetes. In addition we analyzed HbA1c each week for 8 weeks post dona-
tion, a time interval after which blood donors are eligible to donate again.
Unanswered questions and future research
Optimal ferritin status, in combination with vitamin status and kidney function is essential for
effective erythropoiesis. It became apparent that non-diabetic blood donors with a normal fer-
ritin concentration predonation had a significantly larger reduction in HbA1c than blood
donors with low ferritin concentration. As the effectiveness of erythropoiesis after whole blood
donation is dependent on sufficient iron stores, blood donors with normal ferritin concentra-
tions will have a more effective erythropoiesis than blood donors with a low ferritin, therefore
leading to a greater reduction in HbA1c. As we observed the largest reductions in HbA1c in the
second half of this study, the total influx of newly formed erythrocytes seems to be maximal in
week 4–8 after whole blood donation. Ferritin concentration is an important predictor of the
degree of HbA1c reduction after whole blood donation in non-diabetic blood donors. How-
ever, this is not applicable to blood donors with type 2 diabetes. In patients with type 2 diabe-
tes, both newly and previously diagnosed, elevated ferritin concentrations have been reported
before [15,16]. Possible explanations for this could be high iron body stores or an acute-phase
reaction and therefore may reflect inflammation [15–17]. As there was no significant relation
between ferritin concentration and the maximum reduction in HbA1c in blood donors with
type 2 diabetes, it is unlikely that elevated iron body stores are the reason for higher ferritin
concentrations. This makes it more likely that inflammation is the main cause of higher ferri-
tin concentrations in blood donors with type 2 diabetes. In addition, the number of whole
blood donations per year will affect body iron stores. Although non-diabetic blood donors
donated significantly more blood one year before the start of this study (Table 1), there was no
significant difference between both groups in HbA1c decrease, suggesting that a higher ferritin
concentration in blood donors with type 2 diabetes does not reflect the true iron body stores
available for erythropoiesis and may even conceal a possible iron deficiency. Taking the other
confounding factors into account, these were not associated with changes in HbA1c (data not
shown).
Most blood donors didn’t reach their predonation HbA1c concentration at the end of the
study. As the study used a follow-up period of 8 weeks, it is not possible to give an advice on
when the HbA1c has returned to its predonation concentration and when it can be reliably
used by the general practitioner or internist for treatment evaluation or diagnosis of type 2 dia-
betes. Blood donors are eligible to donate again 8 weeks after the previous donation, with a
maximum of 5 times a year for males and 3 times for females. Theoretically this could lead to a
sequential reduction of HbA1c resulting in a new steady state which will be lower than the true
HbA1c concentration. It should be stressed that reduction of HbA1c due to whole blood dona-
tion does not reflect a general decrease in advanced glycation end products and therefore is
not associated with a decreased risk of developing complications associated with type 2
diabetes.
Recommendations
Physicians who are counselling patients with type 2 diabetes who are blood donor or want to
become a blood donor, should take into account that blood donation can result in a significant
reduction of HbA1c for at least two months after whole blood donation. Therefore we recom-
mend patients with type 2 diabetes who donate blood to have at least a 4 month interval
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between blood donations. Measurement of HbA1c should preferably be performed at the end
of this 4 month interval.
Supporting Information
S1 Dataset. HbA1c blood donation raw data 2017.
(XLSX)
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